Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Forbes car reviewer that owns a Volt said that the Bolt would be his first choice if he wants an EV right now so why are you thinking of getting a Volt instead.
ABT/STJ more on ICD hackability from FDA aside from the issue of cya implantations.
http://www.dicardiology.com/article/fda-confirms-cybersecurity-vulnerabilities-st-jude%E2%80%99s-implantable-cardiac-devices-merlin?eid=333568152&bid=1630615
I sold some atm CC's on buyout rumors. Even if there is some truth to the rumor, I found it silly that MDVN purchase was used as an example to justify guesses of BO price. MDVN had solid revenues and xtandi label expansion is certain.
I would be surprised if Indian generic Harvoni is not already available in China for those that want treatment without waiting. http://hepatitisctreatment.homestead.com/buying-generic-harvoni-online.html
This was already mentioned in a prior PR about that special patient with excellent response.
http://www.fortressbiotech.com/2016-11-21%20Mustang%20Oral%20Presentation%20Data%20Announcement%20FINAL.pdf
Quaint but I admit that I thought the same 8 years ago, that Moore's law doesn't work for solar PV and wind turbines. Works well enough - Time scale is stretched but still compounds to a huge difference in 8 years. Opportunities for floating platforms and existing o&g fabricators will fit right in.
http://www.nytimes.com/2016/09/30/business/energy-environment/offshore-wind-farms-see-promise-in-platforms-that-f.html?_r=0
RE AF's M&A opinion - it is meaningless without a time frame or milestone. I am wishing for a bigger reversion to some arbitrary moving average here. Please Santa.
IMO yes and only a tiny sliver of undersea canyons are affected and the blocks proposed by majors are not affected. Bloomberg has a map. Even in the Arctic, there would be plenty of state waters to go after if majors have the appetite. Statoil goes after wind offshore NJ/NY and goes after deepwater Pemex blocks. That's pretty good calibration of how risks will be spread for the next few years. And there are plenty of discoveries off both coasts of Africa awaiting risk capital as BP has done.
On a related topic, I saw a Toyota Murai this week. A bulky car that I would describe as a Camry after an allergic reaction. Where is the hydrogen station I wondered.
Probably saving them from wasting capital. In one article I read about this, the highest bid for one the arctic region blocks was $870K. LOL. They may as well play the powerball. BP is with it's recent purchases show the lower risk path to gain sizable reserves. If they teally want to take risks, Pemex is due to make availabe GOM blocks close to existing infrastructure.
Statoil - Energy from offshore Atlantic, and you don't have to drill $100M holes followed by another several years of platform construction and installation and associated costs.
http://www.marinelog.com/index.php?option=com_k2&view=item&id=24431:statoil-is-winning-bidder-in-nyoffshore-wind-lease-sale&Itemid=230
It will be interesting to see the level of interest, winning bidders and prices. I would expect more Shell-BG magnitude M&A if the majors have more certainty about future demand.
Not sure why this is made out to be a big surprise as Artic region contains a lot of trapped methane in soils and permafrost. I haven't looked recently at the ice coverage map but it seems to have shrunked quite a bit in the last decade and 10X release in methane was theorised years ago. I doubt it has anything to do with rice production as population increase cannot explain a 10X increase in atmospheric methane. https://www.eurekalert.org/pub_releases/2016-12/fe-sim120916.php
RE "At issue are the Arctic and Atlantic waters that the Obama administration excluded from future drilling leases. "
Obama had ambitious plans to open up the Atlantic OCS for leasing and had to withdraw when BP eff it up with Macondo. As it turns out, BP probably ended up saving a lot of money for the rest of the industry with the vast shale resources being succef=ssfully developed. Shell had done quite a bit of exploration r&d on eastern OCS and it is mostly gas. As for the Arctic waters, forget about that. It will be economically difficult. Even more so now than when oil prices were double what it is now.
What pricing and market share assumptions did you use on G/P ?
MDT - Results from 3rd generation arctic front balloon catheter for paroxysmal AF ablation looks good.
http://www.heartrhythmjournal.com/article/S1547-5271(16)30620-8/pdf
ALKS 7119 terminated because of AEs.
Oh look, ARIA is dragging IBB/XBI up today. LOL. Denner doing a great job today holding up the universe.
"The pricing of that sole drug has Ariad in the headlines and brought down the whole biotech sector. "
Wow. That statement is as delusional as saying there is uni-directional volatility in biotech stocks.
Prime example being AGN's positive mention in Barron's being dumped.
Xtandi impacts 50X times as many patients as Pona and it is a much more consequential issue when it comes to pricing. Yet all the noise and outrage has resulted in ZERO action as far as I can tell.
Whatever happened to the proposed Xtandi hearing that a couple of congressman suggested?
http://www.fiercepharma.com/regulatory/updated-astellas-cancer-med-xtandi-draws-fire-as-u-s-lawmakers-demand-a-pricing-hearing
Intuitive Surgical and Fosun to collaborate on catheter robotics for lung procedures.
http://investor.intuitivesurgical.com/mobile.view?c=122359&v=203&d=1&id=2206833
There is a range of responses. When she was still able to communicate, we could tell whether meds worked fairly quickly 1-2 weeks and we can tell via remote monitoring sleep patterns and daytime hallucinations. It got more and more difficult with the loss of communication ability.
I am not sure what a reasonable cost would be given the choices of assisted living vs skilled nursing. It is a mute point for my mother since she passed but I would have wanted her to try it if it was available to her. She was really having a tough time with hallucinations and not getting enough good sleep and that made if difficult for the care givers and offsprings. Either way, end of life care is expensive and is it a quality of life issue for both the afflicted and the caregivers. IMO 24K for a couple of years of much better quality life is worth it. I am not sure the SSRI and the rest of the meds made any difference or if it made things worse. With a 30 free trial, one should be able to tell whether it is worth the expense.
More details on private placement filed after last Friday's close. In total $24M of preferred shares priced at 0.65/share and it also pays a dividend of 6% that accumulates until the company is sold. Then there are $25.8M worth of warrants exercisable at 0.70/share in the future. The current EV is around $80M compared to $35M prior to PP. The preferred owners of the company gets upside, much less so for the common shareholders unless the company gets sales growth going soon. Comparable EV for CVRS is around $110M.
Pricing of warrants adjusted up to 0.70 from 0.65 according to S-8. Closing price prior to PR was 0.59.
http://ir.stereotaxis.com/phoenix.zhtml?c=179896&p=irol-SECText&TEXT=aHR0cDovL2FwaS50ZW5rd2l6YXJkLmNvbS9maWxpbmcueG1sP2lwYWdlPTExMTU2OTAxJkRTRVE9MCZTRVE9MCZTUURFU0M9U0VDVElPTl9FTlRJUkUmc3Vic2lkPTU3
Private placement and retirement of debt. Positive steps IMO.
http://globenewswire.com/news-release/2016/09/27/874919/0/en/Stereotaxis-Announces-Multiple-Positive-Strategic-Updates.html?f=22&fvtc=9&fvtv=United%20States
Baird Q&A presentation
http://wsw.com/webcast/baird46/enta/index.aspx
RE - treatment of VT patients - ICD implants and ablations current guidelines
http://congress365.escardio.org/Presentation/131516
"treatment of ventricular arrhythmias - State of the art"
The safe mode referred to would be factory default settings for pacing and shocks. The problem with safe mode is that settings are very conservative and shocks will be administered at low thresholds of PVC/VT. That would run the battery down faster and also increase morbidity. Safe mode pacing would not be an issue.
I think the programming being hackable by anybody other than the electrophysiologist is the primary issue whether one has to do it being 7 feet away or 50 feet away. On a much bigger scale than STJ, NEJM just had an article about the futility of icd/crt in about half the patient population - non-ischemic VT sufferers. I had thought for quite some time that icd/crt were way over prescribed by EPs. Almost as if it is cya procedure that is a great revenue generator for EPs and implant manufacturers.
The muddy waters piece detailed many issues and STJ response seems one dimensional in comparison. sTJ has other things in heart failure and cardiac rhythm management that are well respected and doing well so the piece's comments with regard to extrapolating problems to the heart failure business is a stretch.
Seems awfully cheap here given the installed base of around 180 systems. Service and maintenance revenue alone is $100K per year. Systems are under utilized when averaged over the whole base somewhere around 1 procedure per week. Usage distribution is bimodal with VT ablation coming up everywhere. Say $150K total revenue per system per year currently at 70-80% gross margin. That would be $18M cash flow per year to an interested buyer if the company shutter all new system sales. Just in western EU, there are 400,000 vt patients with ICD/CRT implants and only 5% of them get ablation now when ischemic VT represent >50% of them. All of them should have ablation as an option ideally but there aren't enough expertise to go around. And that is just western EU. USA is the bigger boat with a similar problem of not enough expertise and STXS tool.
"news" was already released when Nasdaq letters about minimum listing requirements were disclosed by the company when the stock traded below $35M market cap and also when the stock traded below $1. In other words not news at all. Unless you don't read the 10Qs. It still boils down to whether the company can sell new systems and increase utilization. The complete lack of transparency with regards to usage of existing installed base and utilization doesn't help. Longs should assume the worse unless that changes, ie no new sales and declining utilization. A couple of upgrades were announced in recent releases .... YAWN.
Why is it curious? I haven't thought much of the role of GCs in bios. I am long some.
Elon Musk during gigafactory tour and interview with Bloomberg seems confident that battery cost will be at or below $100/kwh with existing technology significantly ahead of the originally scheduled 2020. That has huge implications for energy markets and especially the longevity of any oil cycle rebound.
From last 10Q -
Alimera
Under the collaboration agreement with Alimera, as amended in March 2008 (the “Alimera Agreement”), the Company licensed to Alimera the rights to
develop, market and sell certain product candidates, including ILUVIEN, and Alimera assumed all financial responsibility for the development of licensed
products. In addition, the Company is entitled to receive 20% of any net profits (as defined) on sales of each licensed product (including ILUVIEN) by Alimera,
measured on a quarter-by-quarter and country-by-country basis. Alimera may recover 20% of previously incurred and unapplied net losses (as defined) for
commercialization of each product in a country, but only by an offset of up to 4% of the net profits earned in that country each quarter, reducing the Company’s net
profit share to 16% in each country until those net losses are recouped. If Alimera sublicenses commercialization in any country, the Company is entitled to 20% of
royalties and 33% of non-royalty consideration received by Alimera, less certain permitted deductions. The Company is also entitled to reimbursement of certain
patent maintenance costs with respect to the patents licensed to Alimera.
Because the Company has no remaining performance obligations under the Alimera Agreement, all amounts received from Alimera are recognized as
revenue upon receipt or at such earlier date, if applicable, on which any such amounts are both fixed and determinable and reasonably assured of collectability.
Revenue under the Alimera Agreement totaled $35,000 and $70,000 for the three months ended March 31, 2016 and 2015, respectively, and $226,000 and
$25.1 million for the nine months ended March 31, 2016 and 2015, respectively. These revenues consisted of $157,000 of non-royalty sublicense consideration
earned during the three months ended September 30, 2015 and a $25.0 million milestone earned as a result of the FDA approval of ILUVIEN during the three
months ended September 30, 2014, with the remainder having consisted principally of patent fee reimbursements.
I find PSDV intriguing wrt ALIM results. Not sure if there is a sizable moat with regards to bioresorbable microstents.